Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109993 | 0.87 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL5112807 | 0.85 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5112137 | 0.84 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4DPP4 | |
| SCHEMBL5122493 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5109547 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5112611 | 0.77 | CHRNA7 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5111997 | 0.77 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4MMP2 | |
| SCHEMBL5107879 | 0.77 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5111231 | 0.76 | MAPT (0.46) | — | |
| SCHEMBL5109246 | 0.73 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | claimed |
| US-7442694-B2 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-28 | — | — | US | disclosed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | DBH, CHRNA6, DDT | CHRNB2 10/4885CHRNB4 11/4885CHRNA3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.